High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide

J Clin Oncol. 2009 Sep 10;27(26):e101-2. doi: 10.1200/JCO.2009.23.0508. Epub 2009 Aug 3.

Authors

Derrick Soong, Reem Haj, Mova G Leung, Robert Myers, Brian Higgins, Jeff Myers, Sudha Rajagopal

PMID: 19652050
DOI: 10.1200/JCO.2009.23.0508

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibiotic Prophylaxis
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms / drug therapy*
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects
Docetaxel
Fever / chemically induced*
Fever / prevention & control
Granulocyte Colony-Stimulating Factor / therapeutic use
Humans
Neutropenia / chemically induced*
Neutropenia / prevention & control
Taxoids / administration & dosage
Taxoids / adverse effects

Substances

Taxoids
Granulocyte Colony-Stimulating Factor
Docetaxel
Cyclophosphamide